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Abstract
Background Transdermal delivery of contraceptives
offers several advantages over combined oral contracep-
tives (COCs), including effective absorption and the pro-
vision of relatively constant serum concentrations. Ethinyl
estradiol (EE) and the progestin gestodene are well-
absorbed through the skin and, therefore, well-suited for
use in a transdermal contraceptive patch.
Objective The objective of this study was to investigate
the impact of a once-weekly transparent, transdermal patch
delivering low doses of EE and gestodene equivalent to a
COC containing 0.02 mg EE and 0.06 mg gestodene on
hemostasis parameters compared with a monophasic COC
containing 0.03 mg EE and 0.15 mg levonorgestrel.
Methods In this single-center, open-label, randomized,
crossover study, 30 women (aged 18–35 years) received
three cycles of each treatment, separated by a two-cycle
washout period. The primary outcome measure was the
absolute change from baseline in prothrombin fragments
1 ? 2 and D-dimer.
Results For both treatments, prothrombin fragments
1 ? 2 remained stable during the first treatment period, and
increased only slightly in the second period (mean absolute
change 0.025 and 0.028 nmol/L in the novel Bayer patch
and COC groups, respectively). Increases in D-dimer were
observed in both periods (mean absolute change
107.0 ± 147.2 ng/L for the novel Bayer patch and
113.7 ± 159.0 ng/L for the COC). There were no statisti-
cally significant treatment differences in prothrombin
1 ? 2 or D-dimer (p = 0.667 and p = 0.884, respectively)
and no statistically significant treatment sequence or period
effects.
Conclusion A COC containing 0.03 mg EE and 0.15 mg
levonorgestrel and the novel Bayer patch have comparable
influence on hemostatic endpoints. Both treatments were
well-tolerated by subjects.
1 Introduction
The transdermal application of steroid hormones for sys-
temic use is a well-established method of therapy in post-
menopausal women, using patches containing an estrogen
alone or in combination with a progestin [1]. Transdermal
delivery has also been used effectively for contraception. In
Europe, a transdermal contraceptive patch was approved in
2002 that releases ethinyl estradiol (EE) and norelgestro-
min over the 7-day application period, resulting in systemic
exposure comparable to that observed after daily oral
administration of a combined oral contraceptive (COC) pill
containing 0.034 mg EE and 0.0203 mg norelgestromin
[2].1
More recently, a novel, once-weekly contraceptive patch
has been developed with transparent, transdermal tech-
nology to deliver low doses of EE and of gestodene that
result in the same systemic exposure as observed after oral
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administration of a COC containing 0.02 mg EE and 0.06 mg
gestodene (Bayer Pharma AG, unpublished data).
While daily oral contraceptives—currently the most
common form of contraception used by women in the
developed world [3]—are highly efficacious when used
correctly, poor compliance is a common problem, and can
result in greatly reduced efficacy [4]. Furthermore, oral
administration may be associated with rapid and large
fluctuations in serum concentrations [5], the bioavailability
of EE is low (38–48 %) [6], and the use of COCs can also
result in large intra- and inter-individual pharmacokinetic
variability in serum levels [7]. Transdermal delivery offers
several advantages over the oral administration of hor-
mones, including effective absorption and the provision
of relatively constant serum concentrations [5, 8]. These
advantages, in conjunction with the convenience of weekly
patch application, which may increase compliance, suggest
that transdermal hormone delivery may constitute an
attractive option for women who previously felt their
contraceptive choice was limited.
Both EE and gestodene are hormones that are well-
absorbed through the skin. Consequently, they are appro-
priate for transdermal delivery [5, 8]. At present, EE is the
most potent estrogen agonist available [9], and its use in
COCs is well-documented. Gestodene is a well-researched
progestin, with established efficacy and safety, and has
been widely used as a contraceptive agent in Europe for
more than 20 years [10–12]. Furthermore, the good skin
absorption properties of gestodene [13], and the low
absolute dose required for contraceptive efficacy [14],
allow for a small patch size (Bayer Pharma AG, unpub-
lished data).
An increased risk of venous thromboembolism (VTE)
has been reported with use of COCs. This risk has been
attributed predominantly to EE-induced changes in the
concentration of coagulatory and fibrinolytic proteins, as
well as changes in platelet activity [15]. Using a lower dose
of EE may help to ameliorate this risk and reduce the
adverse effects associated with the estrogen component of
COCs [16]. While there is some evidence that COCs
containing lower doses of EE are associated with fewer
negative hemostatic effects [17], the role of third-genera-
tion progestins constitutes a source of continuing debate.
Although there have been attempts to predict VTE risk
through the evaluation of changes occurring in the coagu-
latory system, these surrogate parameters are not generally
accepted. However, analysis of these parameters is
required by the guidelines for the development of steroidal
contraceptives [18]. In general, the effect of third-genera-
tion COCs on coagulatory mechanisms appears to be
minimal, reflecting a balance between the stimulation of
both (pro)coagulant and fibrinolytic factors [19]. Despite
these findings, there are data to suggest that third-genera-
tion COCs can have a substantial effect on hemostatic
balance, and may result in a prothrombotic state among
users. Indeed, there are reports that women using third-
generation COCs are significantly less sensitive to acti-
vated protein C (APC) than women using second-genera-
tion formulations (p \ 0.001); it could be speculated that
these differences may correlate with a higher risk of
thrombosis in third-generation COC users [20]. Further-
more, for both third- and second-generation formulations,
COC-induced increases in the activity of (pro)coagulatory
factors are not always balanced by increased biological
levels of coagulation inhibitors [21]. There is some indi-
cation that transdermal delivery of hormones may reduce
the risk of VTE associated with COC use [22], although the
supporting data are limited, and results from clinical trials
are conflicting [16, 23–25].
To further investigate the effect of transdermal delivery
on hemostatic parameters, we conducted an open-label,
randomized, crossover study of the novel Bayer patch in
comparison to a monophasic COC containing 0.03 mg EE
and 0.15 mg levonorgestrel.
2 Materials and Methods
2.1 Objectives and Study Design
The primary objective of this study was to investigate the
impact of the novel Bayer patch (patch size 11 cm2; con-
taining 0.55 mg EE and 2.1 mg gestodene per patch) on
hemostasis parameters in a 21-day regimen over a treat-
ment period of three cycles, compared with a standard,
monophasic COC containing 0.03 mg EE and 0.15 mg
levonorgestrel per tablet (Microgynon, Bayer Healthcare
AG, Germany). Secondary objectives included assessment
of safety, contraceptive efficacy, bleeding pattern, and
cycle control.
This was an open-label, randomized, crossover study
conducted at a single center in Germany (ClinicalTri-
als.gov identifier: NCT00933179). The study was con-
ducted in accordance with the Declaration of Helsinki, the
International Conference on Harmonisation Guideline on
Good Clinical Practice, and local laws. The design of the
study adheres to the requirements of the European Medi-
cines Agency Committee for Medicinal Products for
Human Use guideline on clinical investigation of steroid
contraceptives in women (EMEA/CPMP/EWP/519/98
Rev1) [18]. The study protocol was approved by a com-
petent Ethics Committee in Berlin, Germany. Informed
consent was obtained from each subject before entry into
the study.
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2.2 Participants
This study recruited healthy women, 18-35 years of age,
who required contraception and who had a normal cervical
smear result either at screening or documented in the last
6 months, and a history of regular cyclic menstrual periods.
Women were excluded if they were pregnant or lactating,
or had fewer than three menstrual cycles since delivery,
abortion, or lactation prior to the start of treatment. Other
main exclusion criteria included the use of other methods
of contraception; undiagnosed abnormal genital bleeding;
obesity [body mass index (BMI) [30.0 kg/m2]; known
hypersensitivity to any of the study drugs; any disease,
condition, or use of medicines that could interfere with the
study medication; or any disease or condition that could
worsen under hormonal treatment.
2.3 Study Treatment
Subjects were randomized (1:1) into one of two treatment
sequences, using a computer-generated randomization list.
Treatment sequence A: administration of three cycles of
the novel Bayer patch (treatment period 1) followed by two
washout cycles and then administration of three cycles of
COC (treatment period 2); or treatment sequence B:
administration of three cycles of COC (treatment period 1)
followed by two washout cycles and then administration of
three cycles of the novel Bayer patch (treatment period 2)
[Fig. 1].
Treatment with the novel Bayer patch consisted of a
21-day regimen administered as part of each 28-day cycle
(one patch per week for 3 weeks followed by a 7-day,
patch-free interval) for three cycles. Each subsequent cycle
started immediately after the end of the patch-free interval
of the previous cycle and was not triggered by the presence
or absence of uterine bleeding. Only one patch was worn at
a time and was self-applied by the subject to the outer
upper arm, abdomen, or buttocks. Within any given cycle,
the three patches were applied to the same application site;
subjects were permitted to switch between the left and right
side of any chosen application site (e.g., left or right outer
upper arms). Application sites could vary from cycle to
cycle. For COC use, one tablet was taken daily for 21
consecutive days, with each subsequent pack starting after
a 7-day, tablet-free interval. During the washout cycles,
subjects were required to use non-hormonal contraception;
condoms, spermicide, or diaphragm were permitted, but
not the calendar or temperature methods.
2.4 Schedule of Visits
The screening visit (visit 1) was performed within
12 weeks prior to the start of the treatment cycle. Before
the start of treatment, two washout cycles (1 and 2) were
required. Visit 2 took place during washout cycle 2 (days
15–21). Visit 3 took place during treatment cycle 3 (days
15–21) in treatment period 1. Before the next treatment
period, another two washout cycles (3 and 4) were
required. Visits 4 and 5 took place during washout cycles 3
and 4 (days 15–21), respectively. Visit 6 took place during
treatment cycle 6 (days 15–21) in treatment period 2. A














Fig. 1 Study overview. a If the subject is a hormonal contraceptive
starter (i.e., has not used hormonal contraceptives for a period of
3 months before starting the study), no washout period was necessary;
b Treatment sequence A: novel Bayer patch containing 0.55 mg EE
and 2.1 mg GSD in period 1, COC containing 0.03 mg EE and 0.15
mg LNG in period 2; c Treatment sequence B: COC containing 0.03
mg EE and 0.15 mg LNG in period 1, novel Bayer patch containing
0.55 mg EE and 2.1 mg GSD in period 2. COC combined oral
contraceptive, EE ethinyl estradiol, EOT end of treatment, GSD
gestodene, LNG levonorgestrel, SOT start of treatment (on the first
day of bleeding), V1 screening visit, V2 baseline–washout cycle 2
(days 15–21), V3 treatment period 1–treatment cycle 3 (days 15–21),
V4 washout cycle 3 (days 15–21), V5 washout cycle 4 (days 15–21)
or baseline for treatment period 2, V6 treatment period 2–treatment
cycle 6 (days 15–21), V7 up to 2 weeks after EOT, but at least 2 days
after the end of the withdrawal bleeding that follows treatment cycle 6
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the last patch or intake of the last tablet (see Fig. 1 for an
overview).
2.5 Primary and Secondary Variables
The primary objective of this study was to investigate the
impact of the two treatments on hemostasis parameters.
The primary variables selected as sensitive activation
markers for coagulation status were the absolute changes in
prothrombin fragments 1 ? 2 and D-dimer following three
treatment cycles with the novel Bayer patch and COC,
respectively. Laboratory assessment of prothrombin frag-
ments 1 ? 2 was made using Enzygnost 1 ? 2 (Siemens,
Munich, Germany), and D-dimer values were assessed
using Asserachrom D-dimer (Roche Diagnostics, Basel,
Switzerland).
Secondary variables consisted of (pro)coagulatory
parameters (fibrinogen, Factor II, Factor VII, and Factor
VIII activity) and anti-coagulatory parameters (anti-
thrombin III, protein C, and protein S). APC resistance was
determined using COATEST reagents (Haemochrom
Diagnostica, Essen, Germany). The APC sensitivity ratio
was measured by the method described by Rosing et al.
[20]. Blood samples were taken after minimal obstruction
of the upper arm and immediate release after venepuncture
at the forearm. Subjects were required to rest in a supine
position and to adhere to a fasting period of at least 12 h
prior to the collection of blood samples.
The numbers of bleeding and spotting, bleeding-only,
and spotting-only days were recorded to determine bleed-
ing pattern, and women kept a daily record of menstrual
bleeding intensity. To analyze cycle control, menstrual
bleeding was classified as withdrawal bleeding (following
scheduled treatment withdrawal), application deviation
bleeding (following unscheduled treatment withdrawal), or
intracyclic bleeding (other).
2.6 Other Efficacy Variables
With regard to the number of unintended pregnancies, all
pregnancies that occurred during the study until 7 days
after removal of the last patch were recorded.
2.7 Other Safety Variables
Other laboratory assessments conducted include hematol-
ogy, plasma chemistry, liver enzymes, sex hormone-
binding globulin, and carbohydrate and lipid metabolism.
Adverse events were assessed throughout the study for
each treatment. Other safety parameters included gyneco-
logical findings, vital signs, body weight, BMI, and cer-
vical smear results.
2.8 Treatment Compliance
Women were required to record the number of COC tablets
(0, 1, or 2) taken each day, the dates new patches were
applied, the patch application site, patch application devi-
ations, the reason for patch removal (if applicable), the
dates they did not wear a patch, and whether back-up
contraception was used. Patch adhesion (e.g., the number
of completely and partially detached patches per cycle) was
also recorded.
2.9 Statistical Analyses
All treatment variables were analyzed using descriptive
statistical methods. The primary analyses of this study were
performed on the absolute changes from corresponding
baseline values for the two primary variables (prothrombin
fragments 1 ? 2 and D-dimer). A normal distribution was
assumed for the absolute change in each parameter.
The treatment effect in either variable was investigated
using an ANOVA model to test for a treatment difference
for each variable. Bonferroni correction was used to
account for multiple testing; therefore, for each of the two
primary hemostatic parameters, a 97.5 % two-sided confi-
dence interval was derived for the treatment difference. For
the secondary variables, descriptive analyses of the abso-
lute and relative changes from corresponding baseline
values were conducted.
While a sample size of 30 women was chosen without
formal statistical power considerations, this number is
commonly used for metabolic studies on contraceptives.
All women who received study drug, and for whom data
from any treatment period were available, were included in
the full analysis set (FAS). The primary analysis of this
study was based on the FAS; this population was also used
for evaluation of safety data.
3 Results
3.1 Subject Disposition and Demographics
A total of 48 women were enrolled onto the study. Of these
women, 18 did not pass the screening process, and 30 were
randomized for treatment (Fig. 2). In total, 15 women were
assigned to each of treatment sequences A and B. One
woman chose to withdraw from the study prior to treatment
(sequence B), and 29 women either started treatment or, for
those who had used a method of hormonal contraception
prior to screening, performed the first washout phase and
then started treatment period 1. For five women in treat-
ment sequence A and three women in treatment sequence
B, previous use of hormonal contraception was reported
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and a first washout phase required. All 29 women com-
pleted treatment period 1 and the second washout phase;
these 29 women constitute the FAS. During the second
washout phase, after treatment with the COC, one woman
in treatment sequence B became pregnant and discontinued
the study. The remaining 28 women started treatment
period 2, which was completed by a total of 26 subjects: 13




Randomized to sequence A
n = 15








Period 1: treatment started
with Novel Bayer Patch
n = 15










Period 2: treatment started
with COC
n = 15
Period 2: treatment started
with Novel Bayer Patch
n = 13




















• Lost to follow-up  1
• Protocol deviation  1
Enrolled
n = 48
Fig. 2 Disposition of subjects. a Subjects using the novel Bayer
patch were regarded as having completed treatment if there were C77
days between ‘‘Last day patch removed’’ and ‘‘First day patch worn’’
in period 2; b The study was completed only if the subject had
completed the treatment period and had performed the follow-up visit.
COC combined oral contraceptive
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(92.9 %) in treatment sequence B. Two subjects discon-
tinued this period prematurely: one was lost to follow-up,
and the other discontinued following a protocol deviation.
The key demographic characteristics of the FAS popu-
lation are summarized in Table 1. Overall, characteristics
were very similar between the treatment groups.
3.2 Primary Hemostasis Parameters
With regard to prothrombin fragments 1 ? 2, no statisti-
cally significant differences were observed between the
treatment groups in either treatment period. While little
change was observed in the first treatment period, an
increase of prothrombin fragments 1 ? 2 was seen in the
second treatment period for both groups (baseline values
0.099 and 0.109 nmol/L in the novel Bayer patch and COC
groups, respectively; absolute changes 0.025 and
0.028 nmol/L in the novel Bayer patch and COC groups,
respectively). Over both treatment periods, the overall
mean absolute change was 0.008 ± 0.042 nmol/L for the
novel Bayer patch group and 0.013 ± 0.043 nmol/L for the
COC group; the treatment difference of 0 (two-sided
97.5 % CI -0.032 to 0.022) was not statistically significant
(p = 0.667). There were no statistically significant treat-
ment sequence or period effects.
Slight differences in D-dimer concentrations were observed
between the treatment groups in both treatment periods;
however, these were not statistically significant. Over both
treatment periods, the overall mean absolute change was
107.0 ± 147.2 ng/L for the novel Bayer patch group and
113.7 ± 159.0 ng/L for the COC group. The treatment dif-
ference of -6.19 (two-sided 97.5 % CI -103.00 to 90.92)
was not statistically significant (p = 0.884).
3.3 Secondary Variables
A summary of the absolute changes in the secondary
coagulation parameters is shown in Table 2. None of these
changes was of clinical or functional significance.
3.4 Other Efficacy Variables
3.4.1 Cycle Control
In the FAS, withdrawal bleeding was experienced by
86.7–100 % of women in all treatment cycles using the
novel Bayer patch, and by 83.3–100 % of women using the
COC, while intracyclic spotting/bleeding was reported by
6.7–30.8 and 7.1–25.0 % of women in all treatment cycles,
respectively.
3.4.2 Contraceptive Efficacy
Although subjects were well-informed and confirmed that
they would use non-hormonal methods of contraception
(condoms were offered and distributed throughout the
study), one woman became pregnant during the second
washout phase following treatment period 1, during which
the woman had taken the COC. All other pregnancy test
results during the course of the study were negative.
3.5 Safety
Due to the crossover design of the study, adverse events
were recorded per treatment regardless of treatment
sequence. At least one treatment-emergent adverse event
was reported by 21 women (72.4 %) using the novel Bayer
Table 1 Subject demographics and baseline characteristics (full analysis set) for treatment sequence A (n = 15), treatment sequence B
(n = 14), and in total (n = 29)
Treatment sequence Aa Treatment sequence Bb Total
Characteristic [mean ± SD (range)]
Age (years) 26.9 ± 5.3 (18–35) 27.2 ± 3.8 (18–32) 27.0 ± 4.6 (18–35)
Height (cm) 167.3 ± 4.5 (161–174) 166.8 ± 7.2 (148–178) 167.1 ± 5.8 (148–178)
Body weight (kg) 62.6 ± 7.0 (51–78) 62.5 ± 9.0 (44–78) 62.6 ± 7.9 (44–78)
BMI (kg/m2) 22.4 ± 2.4 (19–26) 22.4 ± 2.8 (19–29) 22.4 ± 2.6 (19–29)
Race [n (%)]
Caucasian 14 (93.3) 13 (92.9) 27 (93.1)
Asian 1 (6.7) 1 (7.1) 2 (6.9)
BMI body mass index, COC combined oral contraceptive, EE ethinyl estradiol, GSD gestodene, LNG levonorgestrel, SD standard deviation
a Treatment sequence A = transdermal patch containing 0.55 mg EE and 2.1 mg GSD in period 1, COC containing 0.03 mg EE and 0.15 mg
LNG in period 2
b Treatment sequence B = COC containing 0.03 mg EE and 0.15 mg LNG in period 1, transdermal patch containing 0.55 mg EE and 2.1 mg
GSD in period 2
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Table 2 Summary of absolute changes in secondary coagulation parameters (full analysis set)
Parameters Novel Bayer patcha COCb
nc Mean SD nc Mean SD
Primary hemostasis parameters
Prothrombin fragments 1 ? 2 (nmol/L) [reference range 0.07–0.23 nmol/L]d
Period 1: baseline 15 0.1 0.0 14 0.1 0.0
Period 1: treatment cycle 3 15 0.1 0.1 14 0.1 0.1
Period 1: absolute change (baseline to cycle 3) 15 0.0 0.0 14 0.0 0.1
Period 2: baseline 13 0.1 0.0 14 0.1 0.0
Period 2: treatment cycle 3 13 0.1 0.1 13 0.1 0.0
Period 2: absolute change (baseline to cycle 3) 13 0.0 0.0 13 0.0 0.0
Both periods together: absolute change (baseline to cycle 3) 28 0.0 0.0 27 0.0 0.0
D-dimer (nmol/L) [reference range 0.0–500 nmol/L]e
Period 1: baseline 15 174.1 55.4 14 164.2 66.2
Period 1: treatment cycle 3 15 269.5 185.4 14 268.0 179.6
Period 1: absolute change (baseline to cycle 3) 15 95.3 172.8 14 103.8 150.2
Period 2: baseline 13 145.5 85.7 14 164.9 47.7
Period 2: treatment cycle 3 13 265.9 146.4 13 289.5 180.5
Period 2: absolute change (baseline to cycle 3) 13 120.5 116.6 13 124.4 173.5
Both periods together: absolute change (baseline to cycle 3) 28 107.0 147.2 27 113.7 159.0
Thrombin and fibrin turnover (activation marker)
Prothrombin (Factor II) (%) [reference range 70–120 %]
Period 1: baseline 15 99.9 10.0 14 113.4 13.2
Period 1: treatment cycle 3 15 117.2 8.4 14 114.9 11.3
Period 1: absolute change (baseline to cycle 3) 15 17.3 11.7 14 1.5 13.5
Period 2: baseline 13 101.2 15.6 14 101.4 10.1
Period 2: treatment cycle 3 13 118.1 11.6 13 110.5 13.2
Period 2: absolute change (baseline to cycle 3) 13 16.9 15.0 13 9.0 7.2
Baseline (both periods together) 28 100.5 12.7 28 107.4 13.1
Absolute change (both periods together) 28 17.1 13.1 27 5.1 11.4
(Pro)coagulatory parameters
Fibrinogen (g/L) [reference range 1.8–3.5 g/L]
Period 1: baseline 15 2.7 0.5 14 2.7 0.5
Period 1: treatment cycle 3 15 2.7 0.6 14 3.0 1.0
Period 1: absolute change (baseline to cycle 3) 15 0.0 0.7 14 0.2 0.9
Period 2: baseline 13 2.4 0.6 14 2.3 0.5
Period 2: treatment cycle 3 13 2.7 0.8 13 2.5 0.4
Period 2: absolute change (baseline to cycle 3) 13 0.3 0.7 13 0.2 0.4
Baseline (both periods together) 28 2.6 0.5 28 2.5 0.5
Absolute change (both periods together) 28 0.2 0.7 27 0.2 0.7
Factor VII activity (%) [reference range 70–120 %]
Period 1: baseline 15 90.5 18.9 14 109.1 19.6
Period 1: treatment cycle 3 15 112.0 16.6 14 105.9 17.6
Period 1: absolute change (baseline to cycle 3) 15 21.5 15.5 14 -3.2 16.8
Period 2: baseline 13 92.9 17.6 14 96.9 17.1
Period 2: treatment cycle 3 13 118.4 17.2 13 97.7 16.3
Period 2: absolute change (baseline to cycle 3) 13 25.5 12.2 13 3.4 7.9
Baseline (both periods together) 28 91.6 18.0 28 103.0 19.1
Absolute change (both periods together) 28 23.3 14.0 27 0.0 13.5
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Table 2 continued
Parameters Novel Bayer patcha COCb
nc Mean SD nc Mean SD
Factor VIII activity (%) [reference range 70–150 %]
Period 1: baseline 15 90.1 9.9 14 88.7 17.6
Period 1: treatment cycle 3 15 99.0 9.5 14 96.4 22.5
Period 1: absolute change (baseline to cycle 3) 15 8.9 11.3 14 7.7 11.8
Period 2: baseline 13 90.9 18.4 14 89.4 12.8
Period 2: treatment cycle 3 13 96.0 21.4 13 94.5 13.7
Period 2: absolute change (baseline to cycle 3) 13 5.1 9.8 13 4.2 10.2
Baseline (both periods together) 28 90.5 14.2 28 89.1 15.1
Absolute change (both periods together) 28 7.1 10.6 27 6.0 11.0
Anti-coagulatory parameters
Anti-thrombin III activity (%) [reference range 75–125 %]
Period 1: baseline 15 97.2 9.3 14 97.6 10.2
Period 1: treatment cycle 3 15 98.8 7.5 14 99.6 7.0
Period 1: absolute change (baseline to cycle 3) 15 1.6 7.8 14 2.0 6.8
Period 2: baseline 13 98.9 6.3 14 99.6 4.4
Period 2: treatment cycle 3 13 96.8 8.5 13 96.9 6.1
Period 2: absolute change (baseline to cycle 3) 13 -2.1 4.7 13 -1.9 5.7
Baseline (both periods together) 28 98.0 7.9 28 98.6 7.8
Absolute change (both periods together) 28 -0.1 6.7 27 0.1 6.5
Protein C activity (%) [reference range 70–150 %]
Period 1: baseline 15 102.4 17.8 14 106.1 15.5
Period 1: treatment cycle 3 15 106.1 13.3 14 111.9 17.0
Period 1: absolute change (baseline to cycle 3) 15 3.7 10.6 14 5.7 11.4
Period 2: baseline 13 101.9 19.5 14 97.7 11.0
Period 2: treatment cycle 3 13 114.0 20.7 13 103.2 12.3
Period 2: absolute change (baseline to cycle 3) 13 12.1 8.4 13 7.3 10.2
Baseline (both periods together) 28 102.2 18.3 28 101.9 13.9
Absolute change (both periods together) 28 7.6 10.4 27 6.5 10.6
Protein S activity (%) [reference range 52–118 %]
Period 1: baseline 15 80.9 11.7 14 74.6 11.8
Period 1: treatment cycle 3 15 77.7 10.1 14 81.2 9.0
Period 1: absolute change (baseline to cycle 3) 15 -3.1 6.9 14 6.6 12.8
Period 2: baseline 13 79.7 9.0 14 82.6 9.2
Period 2: treatment cycle 3 13 70.6 10.6 13 82.9 10.4
Period 2: absolute change (baseline to cycle 3) 13 -9.1 5.4 13 -0.3 9.3
Baseline (both periods together) 28 80.3 10.3 28 78.6 11.2
Absolute change (both periods together) 28 -5.9 6.8 27 3.3 11.6
APC resistance (ratio) [reference range 2.0–5.0]
Period 1: baseline 15 3.1 0.3 14 3.2 0.5
Period 1: treatment cycle 3 15 3.0 0.4 14 3.0 0.4
Period 1: absolute change (baseline to cycle 3) 15 -0.1 0.4 14 -0.2 0.3
Period 2: baseline 13 3.3 0.6 14 3.2 0.3
Period 2: treatment cycle 3 13 2.9 0.4 13 3.1 0.4
Period 2: absolute change (baseline to cycle 3) 13 -0.4 0.2 13 -0.1 0.2
Baseline (both periods together) 28 3.2 0.5 28 3.2 0.4
Absolute change (both periods together) 28 -0.2 0.3 27 -0.1 0.3
230 W. Junge et al.
patch and 18 (62.1 %) using the COC; these were most
frequently nasopharyngitis [13 (44.8 %) and 12 (41.1%)
women, respectively] and headache [4 (13.8 %) and 3
(10.3 %) women, respectively]. Twelve events were con-
sidered to be treatment related, and were experienced by
five women (17.2 %) in the novel Bayer patch group and
two (6.9 %) in the COC group. All were mild to moderate
in intensity. No women discontinued the study prematurely
due to adverse events and no serious adverse events or
deaths were reported.
3.6 Treatment Compliance
Overall, compliance with the novel Bayer patch was good,
with women wearing the patch an estimated 99.9 %
(±0.38; range 98.5–100.0) of the required 21 days. Com-
pliance with COC treatment was also good, with an esti-
mated 98.6 % of women (±2.50; range 90.5–100.0) taking
the expected 63 tablets over three cycles.
4 Discussion
The aim of this crossover study was to examine the impact
of the novel Bayer patch and a COC on prothrombin
fragments 1 ? 2 and D-dimer in healthy women over two
treatment periods, each comprising three treatment cycles.
The aforementioned hemostasis parameters were selected
because they are sensitive indicators of coagulation and
fibrinolysis activation; the comparator COC was chosen as
a gold-standard, reference monophasic COC to comply
with the European Medicines Agency Committee for
Medicinal Products for Human Use guideline on clinical
investigation of steroid contraceptives in women, which
states that a product containing levonorgestrel and EE
(150/30 lg) or desogestrel and EE (150/30 lg) is appro-
priate as a comparator where VTE risk has been established
in observational studies [18].
While prothrombin fragment 1 ? 2 levels were stable
(first treatment period) or slightly increased (second treat-
ment period) in response to both treatments, increases in D-
dimer were observed under both treatments and in both
treatment periods; however, the differences in the changes
between treatment groups were neither statistically nor
clinically significant. The observed increase for D-dimer in
both treatment periods, and for prothrombin fragments
1 ? 2 in the second period, implies that the overall balance
between the different factors influencing hemostasis was
maintained on an increased level.
With regard to changes in the secondary hemostasis
parameters, both treatments showed a slight increase in
activation marker levels; however, in most cases, these
increased values did not exceed their upper reference
limits. There were no, or minimal, changes in (pro)coag-
ulatory factors with either treatment, except for Factor VII
activity, which increased in both treatment periods with the
novel Bayer patch. In both treatment sequences, the bal-
ance of the coagulatory system appeared to be maintained
at an increased level for both the pro- and the anti-coagu-
latory parameters. This is consistent with an increase in
fibrin turnover.
It is difficult to correlate changes in individual hemos-
tasis parameters with the clinical endpoint of VTE. Com-
parative pharmacodynamics data may indicate possible
Table 2 continued
Parameters Novel Bayer patcha COCb
nc Mean SD nc Mean SD
APC sensitivity (ratio) [reference range 0.9–2.2]
Period 1: baseline 15 2.0 0.9 14 2.4 1.3
Period 1: treatment cycle 3 15 3.7 1.1 14 4.5 1.4
Period 1: absolute change (baseline to cycle 3) 15 1.7 0.6 14 2.1 1.0
Period 2: baseline 13 2.3 1.4 14 1.8 0.9
Period 2: treatment cycle 3 13 4.8 1.4 13 3.3 1.2
Period 2: absolute change (baseline to cycle 3) 13 2.6 0.8 13 1.4 0.8
Baseline (both periods together) 28 2.1 1.2 28 2.1 1.2
Absolute change (both periods together) 28 2.1 0.8 27 1.8 1.0
APC activated protein C, COC combined oral contraceptive, EE ethinyl estradiol, GSD gestodene, LNG levonorgestrel, SD standard deviation
a Novel Bayer patch = 0.55 mg EE and 2.1 mg GSD
b COC = 0.03 mg EE and 0.15 mg LNG
c n = total number of subjects who received treatment. Note: subjects treated in period 1 are different from those treated in period 2
d Treatment difference = 0.0, two-sided 97.5 % CI: 0.0–0.0, p value of test for treatment difference = 0.667
e Treatment difference = -6.2, two-sided 97.5 % CI: -103 to 90.9, p value of test for treatment difference = 0.884
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differences between products, but there are no generally
accepted surrogate endpoints for the risk of VTE [18]. As
expected, the evaluation of both the primary and secondary
parameters in this study shows that individual hemostasis
parameters are changed by both treatments. This has been
well-documented for other low-dose combined hormonal
contraceptives [26–28]. Overall, the simultaneous changes
in pro- and anti-coagulatory parameters seen in this study
do not suggest a difference in VTE rate for the novel Bayer
patch compared with currently marketed low-dose COCs.
The profile of adverse events recorded during the course
of the study indicated that both treatments were well-
tolerated. In addition, no safety events of clinical signifi-
cance were observed, and bleeding pattern and cycle control
were, in general, comparable between the two treatments.
Both the novel Bayer patch and the COC showed good
contraceptive efficacy in this study, with no pregnancies
occurring during either treatment. One pregnancy occurred
during the second washout phase of this study; however, this
occurred after intake of the last COC tablet.
Despite these favorable results, caution should be taken
when interpreting these findings with the aim of predicting
VTE risk among users of different hormonal contracep-
tives. Although comparative pharmacodynamic data may
be used to indicate possible differences between products,
there are no generally accepted surrogate endpoints. In
addition, it should also be noted that the inability of this
study to find any differences between treatments may be a
reflection of its small sample size and relatively short
treatment duration. In addition lipid metabolism was not
assessed in the present study. However, study data have
shown that low-density lipoprotein cholesterol levels
(LDL-C) decrease and triglyceride and high-density lipo-
protein cholesterol (HDL-C) levels increase from baseline
levels after treatment with a contraceptive preparation that
contains gestodene and EE. These changes resulted in an
increased HDL-C/LDL-C ratio, demonstrating that the
contraceptive had an anti-atherogenic effect [29].
5 Conclusion
The results of this crossover, comparative study demon-
strate that both the novel Bayer patch delivering low doses
of EE and gestodene and a low-dose, monophasic COC
containing EE and levonorgestrel have comparable influ-
ence on hemostatic endpoints. Both treatments were well-
tolerated by subjects, and no clinically significant labora-
tory changes were observed.
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